Atrioventricular block related to liposomal amphotericin B

Detalhes bibliográficos
Autor(a) principal: Sanches, B
Data de Publicação: 2014
Outros Autores: Nunes, P, Almeida, H, Rebelo, M
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.10/2296
Resumo: Atrioventricular block can occur in normal children, young adults or athletes. It is also associated with underlying heart disease or occurs as a drug adverse effect. Amphotericin B is used in the treatment of invasive fungal infections. Cardiac toxicity is a rare adverse reaction. We report the case of a 9-month girl, admitted in the paediatric intensive care unit with cytomegalovirus pneumonitis. During hospitalisation the patient developed a systemic fungic infection and was medicated with liposomal amphotericin B. On the third day of treatment she began repeated episodes of bradycardia with spontaneous reversion. The investigation revealed a second-degree atrioventricular block. We excluded the misplacement of the central catheter, myocarditis or structural cardiomyopathy and suspended amphotericin. After 8 days, the bradycardia episodes ceased what was consistent with the drug's half-life. Amphotericin cardiotoxic mechanism is still unclear. It may be related with alteration of myocardial membrane depolarisation.
id RCAP_adb4ab98672c1294e4ad776c214769b5
oai_identifier_str oai:repositorio.hff.min-saude.pt:10400.10/2296
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Atrioventricular block related to liposomal amphotericin BAtrioventricular blockAmphotericin BAntifungal agentsCardiotoxicityAtrioventricular block can occur in normal children, young adults or athletes. It is also associated with underlying heart disease or occurs as a drug adverse effect. Amphotericin B is used in the treatment of invasive fungal infections. Cardiac toxicity is a rare adverse reaction. We report the case of a 9-month girl, admitted in the paediatric intensive care unit with cytomegalovirus pneumonitis. During hospitalisation the patient developed a systemic fungic infection and was medicated with liposomal amphotericin B. On the third day of treatment she began repeated episodes of bradycardia with spontaneous reversion. The investigation revealed a second-degree atrioventricular block. We excluded the misplacement of the central catheter, myocarditis or structural cardiomyopathy and suspended amphotericin. After 8 days, the bradycardia episodes ceased what was consistent with the drug's half-life. Amphotericin cardiotoxic mechanism is still unclear. It may be related with alteration of myocardial membrane depolarisation.BMJ Pub. GroupRepositório do Hospital Prof. Doutor Fernando FonsecaSanches, BNunes, PAlmeida, HRebelo, M2019-06-21T14:30:18Z2014-01-01T00:00:00Z2014-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.10/2296engBMJ Case Rep. 2014 Jun 6;2014. pii: bcr2013202688.1757-790X10.1136/bcr-2013-202688info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-09-20T15:52:59Zoai:repositorio.hff.min-saude.pt:10400.10/2296Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:53:15.001636Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Atrioventricular block related to liposomal amphotericin B
title Atrioventricular block related to liposomal amphotericin B
spellingShingle Atrioventricular block related to liposomal amphotericin B
Sanches, B
Atrioventricular block
Amphotericin B
Antifungal agents
Cardiotoxicity
title_short Atrioventricular block related to liposomal amphotericin B
title_full Atrioventricular block related to liposomal amphotericin B
title_fullStr Atrioventricular block related to liposomal amphotericin B
title_full_unstemmed Atrioventricular block related to liposomal amphotericin B
title_sort Atrioventricular block related to liposomal amphotericin B
author Sanches, B
author_facet Sanches, B
Nunes, P
Almeida, H
Rebelo, M
author_role author
author2 Nunes, P
Almeida, H
Rebelo, M
author2_role author
author
author
dc.contributor.none.fl_str_mv Repositório do Hospital Prof. Doutor Fernando Fonseca
dc.contributor.author.fl_str_mv Sanches, B
Nunes, P
Almeida, H
Rebelo, M
dc.subject.por.fl_str_mv Atrioventricular block
Amphotericin B
Antifungal agents
Cardiotoxicity
topic Atrioventricular block
Amphotericin B
Antifungal agents
Cardiotoxicity
description Atrioventricular block can occur in normal children, young adults or athletes. It is also associated with underlying heart disease or occurs as a drug adverse effect. Amphotericin B is used in the treatment of invasive fungal infections. Cardiac toxicity is a rare adverse reaction. We report the case of a 9-month girl, admitted in the paediatric intensive care unit with cytomegalovirus pneumonitis. During hospitalisation the patient developed a systemic fungic infection and was medicated with liposomal amphotericin B. On the third day of treatment she began repeated episodes of bradycardia with spontaneous reversion. The investigation revealed a second-degree atrioventricular block. We excluded the misplacement of the central catheter, myocarditis or structural cardiomyopathy and suspended amphotericin. After 8 days, the bradycardia episodes ceased what was consistent with the drug's half-life. Amphotericin cardiotoxic mechanism is still unclear. It may be related with alteration of myocardial membrane depolarisation.
publishDate 2014
dc.date.none.fl_str_mv 2014-01-01T00:00:00Z
2014-01-01T00:00:00Z
2019-06-21T14:30:18Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.10/2296
url http://hdl.handle.net/10400.10/2296
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv BMJ Case Rep. 2014 Jun 6;2014. pii: bcr2013202688.
1757-790X
10.1136/bcr-2013-202688
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BMJ Pub. Group
publisher.none.fl_str_mv BMJ Pub. Group
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130399659524096